

**From:** Houck, Christina M  
**Sent:** Tuesday, June 07, 2016 12:31 PM  
**To:** KSmyth@paxvax.com  
**Subject:** STN 125597/0 IR regarding Amendment 45  
**Importance:** High

Dear Kevin,

We have the following Information Request to PaxVax's item #6 in Section 1.11.3 titled 'Clinical Information Amendment' submitted in Amendment 45 on June 6, 2016:

1. In the revised version of Table 16 from the Integrated Summary of Effectiveness you provided N as the total number of subjects randomized and n as the denominator in the calculation. Please revise this table so that N=the total number of subjects with measurements at baseline and 10 days post-vaccination and n= the number of subjects who seroconverted.

Please respond by COB tomorrow, Wednesday, June 8, 2016.

Kind Regards,

Christina

Christina Houck

Regulatory Project Manager  
Food and Drug Administration  
Center for Biologics Evaluation and Research  
Office of Vaccines Research and Review

10903 New Hampshire Avenue

White Oak Bldg. 71

Silver Spring, MD 20993

Tel: [301-796-2640](tel:301-796-2640)

Fax: [301-827-3532](tel:301-827-3532)

Email: [christina.houck@fda.hhs.gov](mailto:christina.houck@fda.hhs.gov)

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.